Infectious disease patent intelligence

US 12295940

Viral inhibitors, the synthesis thereof, and intermediates thereto

Takeda Pharmaceutical Company Limited · Granted Tue May 13 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 08 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

US 12172969

Deuterated secnidazole for use in the treatment of bacterial vaginosis and methods and uses thereof

EVOFEM BIOSCIENCES, INC. · Granted Tue Dec 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

US 11931463

All-in-one fixed-dose combination for treating Helicobacter pylori infection

RedHill Biopharma Ltd. · Granted Tue Mar 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

US 11878011

Method for eradicating Helicobacter pylori infection in patients regardless of body mass index

RedHill Biopharma Ltd. · Granted Tue Jan 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

US 11744828

Regimens of tafenoquine for prevention of malaria in malaria-naïve subjects

The Government of the United States, as represented by the Secretary of the Army · Granted Tue Sep 05 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 31 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

CA 3174748

UTILISATION DE MASITINIB POUR LE TRAITEMENT DE LA MALADIE A CORONAVIRUS 2019 (COVID-19)

AB SCIENCE [FR] · Granted Thu Oct 14 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Oct 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

US 11135172

Rifabutin-based compositions and methods for treating Helicobacter pylori infection

RedHill Biopharma Ltd. · Granted Tue Oct 05 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10888558

Regimens of tafenoquine for prevention of malaria in malaria-naive subjects

The Government of the United States, as represented by the Secretary of the Army · Granted Tue Jan 12 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10391075

Antiviral treatments

BioCryst Pharmaceuticals, Inc. · Granted Tue Aug 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10342791

Regimens of tafenoquine for prevention of malaria in malaria-naive subjects

The United States of America as represented by the Secretary of the Army · Granted Tue Jul 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8778997

Antiviral treatments

BioCryst Pharmaceuticals, Inc. · Granted Tue Jul 15 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 10 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8664273

Treatment of hepatitis C virus with telaprevir (VX-950) in patients non-responsive to treatment with pegylated interferon-alpha 2A/2B and ribavirin

Vertex Pharmaceuticals Incorporated · Granted Tue Mar 04 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 27 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8420596

Macrocyclic hepatitis C serine protease inhibitors

Enanta Pharmaceuticals, Inc. · Granted Tue Apr 16 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 11 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

US 6057346

Inhibition of retroviral LTR promoters by calcium response modifiers

The United States of America, as represented by the Department of Health and Human Services · Granted Tue May 02 2000 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time)